HomeQuestion
Is there a role for atezolizumab as a first-line agent for metastatic urothelial carcinomas?
1 Answers
Mednet Member
Medical Oncology · University of Washington School of Medicine
The first question is whether the patient can tolerate cisplatin-based chemotherapy and whether or not they received (neoadjuvant or adjuvant) cisplatin-based chemotherapy within at least 1 year (if received peri-operative cisplatin-based therapy, it is a longer discussion regarding re-challenge tha...